Renu K Garg1, Deborah Fulton-Kehoe, Gary M Franklin. 1. Departments of *Epidemiology †Environmental and Occupational Health Sciences ‡Health Services ∥Neurology, University of Washington, Seattle §Washington State Department of Labor and Industries, Olympia, WA.
Abstract
BACKGROUND: The Centers for Disease Control and Prevention recognizes Medicaid as a high-risk population for fatal opioid overdose. Further research is needed to identify factors that put Medicaid patients at increased risk. OBJECTIVE: To determine whether patterns of opioid use are associated with risk of opioid-related mortality among opioid users. DESIGN: This is a retrospective cohort study. PATIENTS: In total, 150,821 noncancer pain patients aged 18-64 years with ≥1 opioid prescription, April 2006 to December 2010, Washington Medicaid. MEASURES: Average daily dose (morphine equivalents), opioid schedule/duration of action, sedative-hypnotic use. RESULTS: Compared with patients at 1-19 mg/d, risk of opioid overdose death significantly increased at 50-89 mg/d [adjusted hazard ratio (aHR), 2.3; 95% confidence interval (CI), 1.4-4.1], 90-119 mg/d (aHR, 4.0; 95% CI, 2.2-7.3), 120-199 mg/d (aHR, 3.8; 95% CI, 2.1-6.9), and ≥200 mg/d (aHR, 4.9; 95% CI, 2.9-8.1). Patients using long-acting plus short-acting Schedule II opioids had 4.7 times the risk of opioid overdose death than non-Schedule II opioids alone (aHR, 4.7; 95% CI, 3.3-6.9). Sedative-hypnotic use compared with nonuse was associated with 6.4 times the risk of opioid overdose death (aHR, 6.4; 95% CI, 5.0-8.4). Risk was particularly high for opioids combined with benzodiazepines and skeletal muscle relaxants (aHR, 12.6; 95% CI, 8.9-17.9). Even at opioid doses 1-19 mg/d, patients using sedative-hypnotics concurrently had 5.6 times the risk than patients without sedative-hypnotics (aHR, 5.6; 95% CI, 1.6-19.3). CONCLUSIONS: Our findings support Federal guideline-recommended dosing thresholds in opioid prescribing. Concurrent sedative-hypnotic use even at low opioid doses poses substantially greater risk of opioid overdose.
BACKGROUND: The Centers for Disease Control and Prevention recognizes Medicaid as a high-risk population for fatal opioid overdose. Further research is needed to identify factors that put Medicaid patients at increased risk. OBJECTIVE: To determine whether patterns of opioid use are associated with risk of opioid-related mortality among opioid users. DESIGN: This is a retrospective cohort study. PATIENTS: In total, 150,821 noncancer painpatients aged 18-64 years with ≥1 opioid prescription, April 2006 to December 2010, Washington Medicaid. MEASURES: Average daily dose (morphine equivalents), opioid schedule/duration of action, sedative-hypnotic use. RESULTS: Compared with patients at 1-19 mg/d, risk of opioid overdose death significantly increased at 50-89 mg/d [adjusted hazard ratio (aHR), 2.3; 95% confidence interval (CI), 1.4-4.1], 90-119 mg/d (aHR, 4.0; 95% CI, 2.2-7.3), 120-199 mg/d (aHR, 3.8; 95% CI, 2.1-6.9), and ≥200 mg/d (aHR, 4.9; 95% CI, 2.9-8.1). Patients using long-acting plus short-acting Schedule II opioids had 4.7 times the risk of opioid overdose death than non-Schedule II opioids alone (aHR, 4.7; 95% CI, 3.3-6.9). Sedative-hypnotic use compared with nonuse was associated with 6.4 times the risk of opioid overdose death (aHR, 6.4; 95% CI, 5.0-8.4). Risk was particularly high for opioids combined with benzodiazepines and skeletal muscle relaxants (aHR, 12.6; 95% CI, 8.9-17.9). Even at opioid doses 1-19 mg/d, patients using sedative-hypnotics concurrently had 5.6 times the risk than patients without sedative-hypnotics (aHR, 5.6; 95% CI, 1.6-19.3). CONCLUSIONS: Our findings support Federal guideline-recommended dosing thresholds in opioid prescribing. Concurrent sedative-hypnotic use even at low opioid doses poses substantially greater risk of opioid overdose.
Authors: Jeanne M Sears; Deborah Fulton-Kehoe; Beryl A Schulman; Sheilah Hogg-Johnson; Gary M Franklin Journal: Public Health Rep Date: 2019-07-31 Impact factor: 2.792
Authors: Adam J Rose; Dana Bernson; Kenneth Kwan Ho Chui; Thomas Land; Alexander Y Walley; Marc R LaRochelle; Bradley D Stein; Thomas J Stopka Journal: J Gen Intern Med Date: 2018-06-14 Impact factor: 5.128
Authors: Katherine B Santosa; Hsou-Mei Hu; Chad M Brummett; Margaret A Olsen; Michael J Englesbe; Eva A Williams; Jennifer F Waljee Journal: Surgery Date: 2019-07-23 Impact factor: 3.982
Authors: Adeleke D Adewumi; Samantha A Hollingworth; Joemer C Maravilla; Jason P Connor; Rosa Alati Journal: CNS Drugs Date: 2018-02 Impact factor: 5.749
Authors: Adam J Rose; Ryan McBain; Megan S Schuler; Marc R LaRochelle; David A Ganz; Vikram Kilambi; Bradley D Stein; Dana Bernson; Kenneth Kwan Ho Chui; Thomas Land; Alexander Y Walley; Thomas J Stopka Journal: J Am Geriatr Soc Date: 2018-11-24 Impact factor: 5.562